Integration of toxicodynamic and toxicokinetic new approach methods into a weight-of-evidence analysis for pesticide developmental neurotoxicity assessment: A case-study with DL- and L-glufosinate.


Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 17 11 2021
revised: 14 02 2022
accepted: 06 04 2022
pubmed: 13 4 2022
medline: 4 5 2022
entrez: 12 4 2022
Statut: ppublish

Résumé

DL-glufosinate ammonium (DL-GLF) is a registered herbicide for which a guideline Developmental Neurotoxicity (DNT) study has been conducted. Offspring effects included altered brain morphometrics, decreased body weight, and increased motor activity. Guideline DNT studies are not available for its enriched isomers L-GLF acid and L-GLF ammonium; conducting one would be time consuming, resource-intensive, and possibly redundant given the existing DL-GLF DNT. To support deciding whether to request a guideline DNT study for the L-GLF isomers, DL-GLF and the L-GLF isomers were screened using in vitro assays for network formation and neurite outgrowth. DL-GLF and L-GLF isomers were without effects in both assays. DL-GLF and L-GLF (1-100 μM) isomers increased mean firing rate of mature networks to 120-140% of baseline. In vitro toxicokinetic assessments were used to derive administered equivalent doses (AEDs) for the in vitro testing concentrations. The AED for L-GLF was ∼3X higher than the NOAEL from the DL-GLF DNT indicating that the available guideline study would be protective of potential DNT due to L-GLF exposure. Based in part on the results of these in vitro studies, EPA is not requiring L-GLF isomer guideline DNT studies, thereby providing a case study for a useful application of DNT screening assays.

Identifiants

pubmed: 35413399
pii: S0273-2300(22)00054-X
doi: 10.1016/j.yrtph.2022.105167
pii:
doi:

Substances chimiques

Aminobutyrates 0
Pesticides 0
phosphinothricin 51276-47-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105167

Informations de copyright

Published by Elsevier Inc.

Auteurs

Sarah Dobreniecki (S)

Office of Pesticide Programs USEPA, Washington, DC, USA.

Elizabeth Mendez (E)

Office of Pesticide Programs USEPA, Washington, DC, USA.

Anna Lowit (A)

Office of Pesticide Programs USEPA, Washington, DC, USA.

Theresa M Freudenrich (TM)

Center for Computational Toxicology and Exposure, Office of Research and Development. US Environmental Protection Agency, Research Triangle Park, NC, USA.

Kathleen Wallace (K)

Center for Computational Toxicology and Exposure, Office of Research and Development. US Environmental Protection Agency, Research Triangle Park, NC, USA.

Amy Carpenter (A)

Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, TN, USA.

Barbara A Wetmore (BA)

Center for Computational Toxicology and Exposure, Office of Research and Development. US Environmental Protection Agency, Research Triangle Park, NC, USA.

Anna Kreutz (A)

Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, TN, USA.

Evgenia Korol-Bexell (E)

Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, TN, USA.

Katie Paul Friedman (KP)

Center for Computational Toxicology and Exposure, Office of Research and Development. US Environmental Protection Agency, Research Triangle Park, NC, USA.

Timothy J Shafer (TJ)

Center for Computational Toxicology and Exposure, Office of Research and Development. US Environmental Protection Agency, Research Triangle Park, NC, USA. Electronic address: shafer.tim@epa.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH